Evidence map›Paper›PMID 39540117›Full record

ArticleJournal of clinical and translational science2024

Lessons learned from the conduct of inpatient clinical trials in a pandemic.

Jane A O'Halloran, Jeremy R Beitler, Lucy K Chung, Mamta K Jain, Akram Khan, Lisa H Merck, Ahmad Mourad, Minn A Oh, Shweta Sharma, Tammy Yokum and 1 more

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jane A O'HalloranWashington University School of Medicine, St. Louis, MO, USA.ORCID https://orcid.org/0000-0001-8265-9471
Jeremy R BeitlerColumbia University, New York, NY, USA.
Lucy K ChungDepartment of Health and Human Services, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.
Mamta K JainUT Southwestern Medical Center, Dallas, TX, USA.
Akram KhanOregon Health and Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0003-3091-632X
Lisa H MerckDepartment of Emergency Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Ahmad MouradDepartment of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0002-3149-597X
Minn A OhOregon Health and Science University, Portland, OR, USA.ORCID https://orcid.org/0009-0008-3727-9611
Shweta SharmaDivision of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Tammy YokumDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Rockville, MD, USA.
Seema U NayakDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Rockville, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic amplified known challenges associated with the conduct of inpatient clinical trials, while also introducing new ones that needed to be addressed. Methods: Stakeholders based in the United States who participated in the conduct of inpatient therapeutic trials for the treatment of COVID-19 as part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines program identified challenges experienced in the conduct of these trials through a series of meeting to discuss and identify common themes. In addition, innovations developed to address these challenges and other potential solutions that may be utilized in future pandemics were highlighted. Results: Six thematic challenges including infection control considerations, the interplay between provision of clinical care and research, competing clinical trials, arduous consenting procedures, onerous procedural requirements, and participant recruitment including achieving representation of diverse populations were identified and are discussed here. Conclusions: Consideration of the lessons learned and recommendation outlined here may allow for more efficient conduct of inpatient clinical trials in future pandemics.

Indexed as

ACTIVclinical trialCOVID-19inpatientpandemic preparedness

Identifiers

PMID39540117
PMCPMC11557273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.